ATS 2018: Higher doses of rifampin appear more effective in fighting TB

Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial. The trial has been published by Gustavo E. Velásquez, MD, MPH, associate physician in the Division of Infectious Diseases at Brigham and Women's Hospital in Boston, and co-authors in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.